Dopamine Transporter PET Imaging in NHP Models | CNS Imaging | Prisys Biotech

In central nervous system (CNS) drug development, the ability to quantitatively assess drug distribution, target engagement, and disease progression in vivo remains a critical challenge. The presence of the blood–brain barrier (BBB), coupled with the anatomical and functional complexity of the brain, significantly limits the utility of conventional ex vivo analyses. These approaches fail to capture dynamic biological processes over time within intact neural systems.

Non-human primates (NHPs), particularly cynomolgus monkeys, offer high translational relevance due to their close homology to human brain anatomy and neurotransmitter systems. When combined with radiotracer-based nuclear imaging, NHP models enable real-time, longitudinal, and quantitative evaluation of molecular processes in the living brain.

At Prisys Biotech, this capability is integrated within a clinical-grade in vivo imaging platform, supporting CNS research from early target validation to translational pharmacology.

Dopamine transporter (DAT) imaging has become a well-established quantitative biomarker for assessing dopaminergic neuron integrity, particularly in Parkinson's disease (PD) and related neurodegenerative disorders.

Using PET/CT imaging with selective radiotracers such as:

• ¹⁸F-FP-CIT
• ¹¹C-FE-PE2I

Prisys enables specific binding to DAT in the striatum, allowing quantitative assessment of dopaminergic neuron loss and functional recovery in NHP models.

In addition, complementary tracers can be applied to broaden mechanistic insights:

• ¹¹C-CFT (DAT imaging)
• ¹⁸F-AV133 (VMAT2 imaging)

These approaches enable quantitative comparison of tracer uptake between lesioned and contralateral brain regions, providing objective molecular endpoints that reduce reliance on subjective behavioral scoring.

Such imaging-derived biomarkers are particularly valuable for evaluating:

• Neuroprotective therapies
• Gene therapies
• Cell-based interventions
• Target engagement of CNS-active compounds

While PET imaging provides ultra-high sensitivity (fM–pM level detection), its spatial resolution is limited when analyzing small or deep brain nuclei.

To address this, hybrid PET/MRI imaging is increasingly applied in CNS research.

This multimodal approach enables:

• PET: quantitative assessment of metabolism, blood flow, and target occupancy
• MRI: high-resolution soft tissue contrast and precise anatomical localization

Through co-registration and image fusion, hybrid PET/MRI allows accurate mapping of:

• Multi-centric lesions
• Deep brain nuclei (e.g., putamen, subthalamic nucleus)
• Regional drug distribution patterns

At Prisys, this integrated imaging strategy supports 3D quantitative analysis with both anatomical and functional resolution, significantly improving the accuracy of lesion characterization and therapeutic evaluation in NHP CNS models.

Prisys Biotech provides a comprehensive clinical imaging platform within its Translational Research Center, equipped with:

• PET-CT and MRI systems adapted for NHP studies
• Clinically trained radiologists with >20 years of experience
• Validated imaging protocols bridging human and NHP applications
• Integrated analysis for lesion quantification and biomarker evaluation

This platform enables:

• Non-invasive longitudinal monitoring
• Reduced need for terminal procedures
• High predictive value for clinical translation

By aligning preclinical imaging methodologies with clinical standards, Prisys ensures that imaging-derived endpoints are directly translatable to human studies, supporting more informed decision-making in drug development.

High-precision nuclear imaging, particularly dopamine transporter PET imaging, provides a robust and quantitative tool for evaluating CNS disease mechanisms and therapeutic efficacy in vivo.

Leveraging clinical-grade imaging infrastructure, radiotracer expertise, and NHP translational models, Prisys Biotech enables:

• Accurate visualization of CNS targets
• Quantitative assessment of drug distribution and target engagement
• Improved prediction of clinical outcomes

These capabilities establish a translational bridge between preclinical research and clinical application, supporting the development of next-generation therapies for neurodegenerative diseases.

Contact Prisys Biotech